Auxilium Pharmaceuticals (AUXL) versus KalVista Pharmaceuticals (KALV) Head to Head Survey
Auxilium Pharmaceuticals (NASDAQ: AUXL) and KalVista Pharmaceuticals (NASDAQ:KALV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
This is a summary of recent ratings and recommmendations for Auxilium Pharmaceuticals and KalVista Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KalVista Pharmaceuticals has a consensus price target of $27.00, indicating a potential upside of 139.79%. Given KalVista Pharmaceuticals’ higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Auxilium Pharmaceuticals.
This table compares Auxilium Pharmaceuticals and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
75.7% of KalVista Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Auxilium Pharmaceuticals and KalVista Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$625,000.00||174.99||-$16.21 million||N/A||N/A|
Auxilium Pharmaceuticals has higher revenue, but lower earnings than KalVista Pharmaceuticals.
KalVista Pharmaceuticals beats Auxilium Pharmaceuticals on 6 of the 8 factors compared between the two stocks.
Auxilium Pharmaceuticals Company Profile
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.